THE OXFORD COMMUNIQUÉ
WITH ALEXANDER GREEN

GREAT PROFITS IN THE COMPANY OF GOOD FRIENDS | SEPTEMBER 1, 2017, VOLUME 30, NO. 9

This Cancer Company Is a Potential Ten-Bagger

Lifespans Are Expanding... Sales Are Skyrocketing



ALEXANDER GREEN

Dear Member,

Americans today are living longer than ever.

That's a bit surprising when you consider that 36% of us are obese. Obesity can lead to diabetes, high blood pressure, stroke, depression and other life-shortening maladies.

Yet we live in an age of nearly miraculous scientific discoveries. Almost every week we hear about some new stem cell research, breakthrough vaccine or innovative gene editing technique like CRISPR.

New medical devices, advanced therapies and lifesaving drugs are extending and improving the lives of millions of Americans.

We own some of the companies responsible for these developments in our portfolios. Consider, for instance, **Laboratory Corp.** (NYSE: LH), **Accelerate Diagnostics** (Nasdaq: AXDX), **Glaukos** (Nasdaq: GKOS), **Intrexon Corp.** (NYSE: XON), **Kite Pharma** (Nasdaq: KITE) and **Stryker Corp.** (NYSE: SYK), to name just a few.

This month, we're adding another.

It's a midcap company with a powerful new cancer therapy and the opportunity to combine it with several other treatments. The possibilities are almost limitless.

The firm doesn't yet have a full year of profitability under its belt. But it won't be long.

Sales are quintupling. And Big Pharma is taking note. The upside risk here may be that the firm gets taken over sooner than we'd like.

The company is the newest addition to our Ten-Baggers of Tomorrow Portfolio.

Anatomy of a Ten-Bagger

When I introduced this portfolio in the *Communiqué* a year ago, one of my colleagues shook his head.

"You've got a lot of guts introducing stocks you expect to rise severalfold," he said, "*eight years* into a bull market."

His comment underscored how differently we think. Most people wonder and worry about how long a stock market rally will continue. But no one knows the answer to that. So serious investors concern themselves with identifying transformative companies that are set to prosper no matter what the economy or markets do.

From the beginning, I've said that the companies in this portfolio must meet seven minimum requirements.

1. They must be tremendous innovators. Companies that rise tenfold or more offer revolutionary technologies, new medical devices, blockbuster drugs, or other cutting-edge products and services.
2. They must experience terrific sales growth. In this case, top-line expansion has to be 30% or more.
3. They must protect their margins. A firm must be able to defend its market niche from competition with patents, trademarks or brand names.
4. They must beat consensus estimates. In the short term, share outperformance is all about beating expectations. Even if a company loses money, it can still register as a significant beat if the loss is smaller than expected.
5. They must be small cap to midcap companies. Mega-corporations simply cannot grow at the high rates of smaller firms.
6. They must have significant insider ownership. Officers and directors have access to all sorts of material, non-public information. That gives them insights into the company's near-term prospects. You should insist on managers who "eat their own cooking." History shows that when top management owns shares, other shareholders are treated well, too.
7. They must be relatively unknown. Once a company becomes a household name, the parabolic move higher is often over. Investors who recognize opportunities early have a substantial advantage.

In our Oxford Trading Portfolio, we sell any stock that closes 25% or more below its closing high or our original entry price. That protects both our principal and our profits.

But the companies in our Ten-Baggers of Tomorrow Portfolio are smaller, more speculative and more volatile. So we use a different sell discipline to avoid stopping out too soon.

Here we sell only when there is a fundamental change in the business outlook or the company misses the quarterly consensus earnings estimate by 25% or more.

How has this strategy panned out? You can see on Page 11.

As I write, the average stock in this portfolio is up more than 27%, even though our average holding period is just 271 days.

And today I have a new addition: **Exelixis** (Nasdaq: EXEL).

The Evolution of Cancer Treatment

Based in San Francisco, Exelixis – from the Greek word for "evolution" – is a biopharmaceutical firm dedicated to the discovery, development and commercialization of new medicines for cancer treatment.

Its drug cabozantinib received regulatory approval in 2012 for patients with metastatic thyroid cancer. Since then, in partnership with several big-name collaborators – including **Bristol-Myers Squibb** (NYSE: BMY) and **Roche Holding** (OTC: RHHBY) – Exelixis has advanced a global clinical development program that is evaluating the drug in more than 45 planned or ongoing clinical trials.

In April 2016, cabozantinib received its second U.S. approval, as a treatment for patients with advanced renal cell carcinoma.

Made in tablet form, it is the first and only single-pill therapy to demonstrate clinically meaningful improvements in patients who have already undergone treatment.

The plan now is to grow beyond these initial collaborations and make the drug the backbone of choice for several other immunotherapy collaborations. The company is now evaluating it alongside several other promising oncology drugs.

A second Exelixis-discovered compound – cobimetinib – also has broad potential as a cancer treatment. It is part of a worldwide collaboration with Genentech – a member of the Roche Group – and is the subject of three pivotal Phase 3 combination trials this year. Good news on any of these fronts could push the company's shares considerably higher.

Exelixis is just making the transformation from development-stage company to commercially viable drugmaker.

In fact, it hit three major milestones in just the last few months.

- It posted its first-ever operating profit. (The company was founded in 1994.)
- It confirmed the effectiveness of its drug for treating kidney cancer.
- It retired nearly all its debt, announcing the repayment of $123.8 million of its notes a year ahead of schedule, saving $12 million in interest expense.

(The last is particularly remarkable since most development-stage companies are continually borrowing to fund their operations while waiting for drug sales to materialize.)

However, many pharmaceutical firms have seen their share prices pressured lately on fears that Congress is intent on forcing drug prices lower.

Leaving aside the fact that this Congress can't even agree on what to have for lunch, the urgent demand for new oncology treatments leaves cancer drug pricing pretty secure.

And given the scarcity of active, differentiated molecules in the biopharmaceutical industry, the cabozantinib franchise is extremely valuable.

Exelixis turned a profit for the first time in the fourth quarter of last year. It continued in the black in the first and second quarter of this year.

Revenue growth was 424% in the March quarter and 173% in the June quarter. Exelixis beat the consensus earnings estimate by an average of more than 80% in each of the last five quarters.

CEO Dr. Michael Morrissey says the company will use its free cash flow to invest in additional clinical trials, boost internal discovery efforts and pursue new licensing opportunities.

As I mentioned, however, one development might end future appreciation at Exelixis before the stock rises severalfold. It is widely rumored to be an acquisition target.

But, short of a buyout, future earnings prospects are attractive indeed.

Action to Take: *Buy **Exelixis** (Nasdaq: EXEL) at market. We will notify you with a* Safety Switch Alert *if the company reports quarterly results 25% or more below the consensus estimate.* ■

Luck vs. Skill

Why Some Folks Resent Your Financial Success

Alexander Green, Chief Investment Strategist, The Oxford Club

In July in Las Vegas, I was supposed to debate author and *New York Times* columnist Robert Frank about his contention that economic success is not primarily due to education, hard work, talent, skill, persistence or resilience... but "luck."

He calls the idea that our society is a meritocracy "a myth."

Unfortunately, Mr. Frank suffered a heart attack recently and was unable to attend.

So author, *Skeptic* magazine founder and *Scientific American* columnist Michael Shermer agreed to take his place, even though he doesn't agree with all of Frank's conclusions.

Shermer kicked off the debate by arguing that we have differences in genetics, upbringing and personal circumstances that may have more to do with our resulting economic success than we care to admit, particularly if we've been highly successful.

This is incontestable, and I didn't quibble.

In this country, for example, if you're born white, male, into a relatively affluent household with nurturing parents, and possess a higher-than-average IQ, you are far more likely to experience economic success than, say, someone who is born to a crack-addicted single mother in inner-city Baltimore.

No one is responsible for his or her circumstances at birth. We should all recognize this – and the effect it has on outcomes in a market-based economy.

Yet Frank argues that even among people of roughly equal circumstances, it is still luck that makes the difference.

In his book *Success and Luck: Good Fortune and the Myth of Meritocracy*, he provides anecdotes to illustrate his point, arguing that plenty of talented people work hard and never experience any great economic success.

This is true, of course. Sometimes our lack of success really is due to circumstances beyond our control.

But is this really the best and most satisfactory explanation for why some individuals experience greater economic success than others?

Of course not.

We know this thanks, in part, to the work of the late Dr. Thomas Stanley, author of *The Millionaire Next Door, The Millionaire Mind* and other best-sellers, who spent a lifetime surveying and studying the habits and characteristics of America's wealthiest men and women.

At the end of 2016, one in nine U.S. households had a net worth of $1 million or more. Stanley discovered that the vast majority of these individuals received no generous inheritance and had no special connections.

Rather they maximized their income, minimized their expenses, religiously saved and invested the difference, and let the money compound for years – and usually decades.

You don't have to be a high income earner to do this. However, you do need discipline, patience... and time.

For example, if, beginning at the age of 25, you invested $190 a month in an S&P 500 index fund – and earned nothing more or less than the market's long-term average annual return of 10% – it would turn into $1,071,574 by the time you turned 65.

According to the U.S. Census Bureau, the U.S. median household income is $56,516. So it requires the average household to save just 4% of its income – or less than 5% post-tax – to hit the seven-figure mark in 40 years.

Even if a household could save only $95 a month, it would still turn into a half-million dollars. That still provides a substantial measure of financial independence.

Yet most Americans don't do anything like this. Why?

Some don't save. Some save but don't invest. Some invest but not successfully. And some invest successfully but can't resist the temptation of spending the money rather than letting it compound.

"No one attributes long-term success in athletics, music, literature, entertainment or the arts to luck. It isn't true in business either."

What Stanley's research reveals is that the vast majority of American millionaires made choices and developed habits that almost invariably led to financial success.

These choices are available to virtually all working men and women.

In his final book, *Stop Acting Rich... and Start Living Like a Real Millionaire*, Dr. Stanley wrote, "I have spent a lifetime identifying and profiling the myths and realities of the rich. Among the least important factors were high academic achievement... and luck."

This is more than just an academic argument. Ideas are powerful. They have consequences.

With that in mind, here are seven good reasons to reject Robert Frank's thesis:

1. <u>It stokes resentment and class envy</u>. Europeans have a long tradition of hostility toward "the rich" – and for good reason. For centuries, most of the wealth there was inherited or stolen (or both).

   Virtually everyone worked for royals, aristocrats and other "nobles" who had done little or nothing to earn what they had.

   Contrast that with America's market-based economy, where every transaction is voluntary and the wealthiest individuals – like Bill Gates and Jeff Bezos – have generally done the most to transform society for the better.

2. <u>It's dispiriting</u>. Am I really supposed to tell David, my 13-year-old son, "Educate yourself. Work hard. Get back up every time you're knocked down. But listen, kid, in the end it's really all about luck"?

3. <u>It's demeaning</u> to those who have sacrificed a great deal – including often the best years of their lives – to achieve their economic success.

   It's particularly insulting to those who have come the furthest – women, blacks, Hispanics, gays, and those with mental or physical handicaps.

   I'd recommend taking a step back before you tell these folks their success was primarily luck.

4. <u>It excuses failure</u> and provides intellectual cover for slackers, shirkers and non-achievers who desperately want to believe that "the economy is rigged" and economic success is *not* about good habits and smart choices.

5. <u>It reveals an unwarranted anti-business bias</u>. When Roger Federer won his eighth Wimbledon title and 19th Grand Slam singles title last month, was your first thought "Wow. That Roger sure is lucky"?

   When you attend a recital at Carnegie Hall, do you walk out saying, "You know, when Itzhak Perlman picks up that violin, I can't believe how lucky he gets"?

   No one attributes long-term success in athletics, music, literature, entertainment or the arts to luck. It isn't true in business either.

6. <u>It provides intellectual justification for high progressive tax rates</u>. Robert Frank and his ilk want to convince people that the economically successful didn't really earn it and don't deserve it. Therefore, social justice demands government confiscation and redistribution.

7. <u>It isn't true</u>. Frank's claims don't just defy common sense and everyday experience. As

I mentioned in previous columns, decades of research and data by Dr. Thomas Stanley reveal them to be false.

Unfortunately, Frank's views have taken root with many. They refer to economically successful individuals as "the fortunate" or "society's lottery winners."

The latter is a particularly low blow. Freely made economic transactions are, by definition, a win-win. Lottery winners receive only what others lose.

Historically, there has been a striking lack of class envy in America. By and large, we have celebrated others' success rather than resenting it.

Some want to change that, to promote the idea that wealth is not the result of personal responsibility, initiative, hard work and intelligent risk-taking.

That view shouldn't go unchallenged. ■

by Alexander Green

This bull market isn't getting any younger... but our *Oxford Communiqué* portfolios aren't getting any less lucrative.

Let's start our review with an innovative business intelligence provider.

TransUnion Delivers Another Great Quarter

In the short term, the primary driver of individual stocks is better-than-expected growth in earnings per share.

TransUnion (NYSE: TRU), a member of our Oxford Trading Portfolio, delivered it again – and for the fourth consecutive quarter – last month.

Net income soared 241% on a 12% increase in sales. And during the June quarter, the company also repurchased $65 million of its shares, bringing this year's total buyback to $133 million.

So let's take a closer look at what's happening here...

TransUnion is one of the world's leading business intelligence providers. Its goal is to help both borrowers and lenders make better-informed decisions.

It does this by helping consumers understand and manage their credit scores and other personal information – and also by partnering with banks, healthcare providers and property managers to help create opportunities.

The right information – analyzed by experienced professionals – enables consumers to learn from the past, navigate the present and deal with the future.

Through easy-to-use online services, TransUnion helps millions of consumers protect and improve their credit.

Accurate credit information is important to everyone. Your credit report includes the names of companies that have extended you credit in the past, loan amounts, credit limits, remaining balances and payment histories, including bankruptcies, foreclosures, lawsuits and liens.

If this information is inaccurate, a lender may demand a higher interest rate – to adjust for greater perceived risk – or deny a loan request altogether.

Inaccurate, derogatory information can lower credit scores. It may even indicate fraudulent activity. But TransUnion allows individuals to quickly and easily resolve a credit report inaccuracy.

At the customer's request, the firm will investigate any credit dispute.

It contacts representatives of the reporting company, supplies them with the relevant information, and instructs them to review the dispute, verify the information, provide a response, update their records and systems, and make the appropriate changes to the customer's credit report.

Investigations are usually completed in less than 30 days. And if the dispute is filed online, you are notified by email and given access to the results of the investigation immediately.

If your claim is correct, you will see a corrected copy of your credit report at the conclusion of the dispute process.

Fixing credit reports is only one service that TransUnion offers.

The company also offers a Credit Lock that – with a single smartphone swipe or mouse click – prevents criminals from using your report to get credit in your name. (And you can unlock it just as easily whenever you need to apply for credit.)

TransUnion also offers Data Breach Solutions to protect online information for businesses.

This is not just a growing business but a vital service. Last year, 15.4 million Americans were victims of identity fraud. (That's someone every two seconds.)

Implementing a program like this protects credit scores as well as business and personal reputations.

TransUnion currently provides credit information and other services to more than 45,000 businesses and over 500 million consumers in 33 countries. It is the third-largest credit bureau in the United States, with annual revenue of more than $1.7 billion.

Credit scores for U.S. consumers reached a record high this spring, while the percentage of Americans deemed to be risky borrowers hit a record low.

It turns out that time doesn't just heal all wounds. It also fixes household balance sheets and credit ratings.

Enough years have passed since the Great Recession that foreclosures and bankruptcies are rolling off Americans' credit reports.

A recent Barclays report reveals that more than 6 million U.S. adults will have personal bankruptcies disappear over the next five years.

Still, not all borrowers are creditworthy. And not all lenders offer competitive terms.

Banks and other lenders have to decide whom to lend to. And consumers, businesses and other organizations want to know whom to borrow from.

So TransUnion offers a vital service.

Looking forward, the company intends to drive earnings higher with a strategy of continued innovation, expansion into new markets and growth overseas, including developing markets like Colombia and India.

With jobs, wages, credit scores and consumer confidence all trending higher, expect TransUnion to outperform in the second half.

Another Urgent Call for REV Group

A popular investment theme of the last few years has been "The Graying of America."

Demographers point out that there are 80 million baby boomers – and 10,000 a day reach retirement age.

This is an active group, far less sedentary than previous generations of retirees.

And in the months and years ahead, their spending will power sales and earnings at hundreds of companies across a variety of sectors.

Of course, there is a downside to aging too: a decrease in overall health and an increase in accidents. For the elderly, just getting into the bathtub or down the stairs involves risk.

That's one of the reasons we have **REV Group** (NYSE: REVG) in the Oxford Trading Portfolio.

Based in Milwaukee, REV Group makes and sells firetrucks, ambulances, buses, RVs and other specialty vehicles. In particular, it is the market share leader in the ambulance business.

If you dial 911 for emergency help, there is a good chance one of its vehicles will answer the call. Every one of its eight leading brands – Marque, McCoy Miller, Road Rescue, Wheeled Coach, AEV, Horton, Frontline and Leader – puts first responders first.

REV Group is also the runner-up in fire vehicles and apparatus (i.e., emergency equipment). When it comes to battling fires, REV brings two of the best firetruck brands in the world to the fight: E-One and KME.

Many towns and cities – under budgetary constraints during the Great Recession – put off buying new firetrucks and ambulances over the last several years.

The replacement demand for the nation's aging emergency vehicles will push near-term sales and earnings higher.

And this will be doubly true when Washington finally gets around to funding its long-promised infrastructure upgrades, one of the few issues today with strong bipartisan support.

REV Group also makes RVs. Recreational vehicles are a tradition for many American travelers, especially retirees, who are more likely to have the time and money to spend on the road.

Demographic trends indicate that this is an area that will generate strong future growth for REV Group. And history shows that people who get into the RV market tend to stay in the RV market.

REV Group also makes a variety of buses, including brands like Champion, Collins, ENC, ElDorado, Federal, Goshen, Krystal and World Trans.

In fact, one of the biggest buyers of the company's specialty buses is Brookdale Senior Living, the nation's largest operator of senior-living communities. It uses the company's shuttle buses to move passengers through its communities, as well as across town or out on the highways.

Business is already exceptional at REV Group. Annual sales are almost $2 billion and are growing 14% year over year. Earnings should hit $1.21 a share this year and rise 40% in 2018.

REV Group Annual Revenue – 2014 to 2016



REV Group is also an aggressive acquirer of other companies.

In late April, for instance, it announced that it was buying Ferrara Fire Apparatus, a leading rescue vehicle manufacturer and supplier. It engineers and builds heavy-duty vehicles for both municipal and industrial customers.

This buyout will create a number of fresh opportunities, including new accounts, an expanded dealership network and increased geographical reach.

Something that adds a measure of safety to this investment is the specialized nature of REV Group's business. There is far less competition in firetrucks and ambulances than in coupes, sedans and SUVs.

In sum, this is a fast-rising company with dominant market share in an expanding industry that is virtually certain to grow in the months and years ahead.

Ryanair Flies Even Higher

Our shares of **Ryanair** (Nasdaq: RYAAY) are up over 65%. Yet there are good reasons to believe the stock still hasn't reached peak altitude.

Based in Dublin, Ryanair isn't just Europe's deepest-discount carrier. It carries more international passengers than any other airline in the world.

The company operates more than 2,000 flights daily from over 200 airports in 33 countries, using more than 400 new Boeing 737-800 aircraft.

Eighty-eight percent of its flights arrive on time, and it cancels fewer flights than any other airline. It also has an unblemished 32-year safety record.

Most major European airlines are heavily unionized. To compete effectively, they would have to get major labor concessions.

That's not likely. And it means traditional network airlines like Lufthansa, Air France and British Airways simply cannot compete.

So expect sales and earnings to continue nose-up. Ryanair has beaten the consensus estimate by double digits in each of the last two quarters.

Ryanair Annual Revenue – 2013 to Present



Earnings per share are likely to hit $1.42 this year and rise another 22% next year.

Why? Let's start with the precipitous drop in oil prices.

The cheaper energy gets, the more Ryanair earns. Fuel is more than a third of the company's costs.

Ancillary revenue is also rising. The company generates sales from in-flight magazines and advertising sold on loading bridges and in airport lounges.

Then there are onboard food and beverage sales, baggage charges, seat upgrades, access to VIP lounges, and priority check-ins.

The expanding global middle class will only increase the demand for travel. In 2009, there were 1.8 billion global flyers. By 2020, there are expected to be 3.2 billion – and 4.9 billion by 2030.

So in late June, Ryanair announced the purchase of 10 more Boeing 737 Max 200 aircraft on top of its existing order for 100 Max 200s.

Why so many new aircraft? Because Ryanair expects to grow its traffic to 200 million customers within seven years.

The new aircraft will reduce fuel consumption by 18%, reduce noise emissions by 40% and offer eight more seats per flight, enabling the company to reduce its already rock-bottom fares even further.

This all bodes well for future profits.

Kite Pharma Gets a Lift From Futuristic Cancer Therapies

The *Communiqué*'s Ten-Baggers of Tomorrow Portfolio is made up of more speculative companies with the potential to rise tenfold or more.

That's a tall order, of course. But our shares of **Kite Pharma** (Nasdaq: KITE) are up 118% since we got in 11 months ago.

Based in Santa Monica, California, Kite is a clinical-stage drug company focused on the development and commercialization of cancer immunotherapy products.

Immunotherapy is the most exciting development in cancer treatment *ever*.

Ordinarily, your immune system seeks out and destroys invaders. That's how it handles viruses and harmful bacteria.

But cancer cells are insidious. They camouflage themselves and trick your body's immune system into believing that they are normal cells. After outsmarting your body's built-in defenses, they metastasize.

Immunotherapies don't target cancer cells. Instead, these drugs – administered through a pill or an IV – trigger your immune system to kill the cancer cells while leaving healthy cells intact.

Kite specializes in engineered T-cell therapy, a biotechnology that has produced dramatic results up to and including complete remission in some patients who have aggressive blood cancers that have not responded to other therapies.

It's called CAR-T therapy. And what looked like science fiction just a few years ago is now the most promising development in cancer research.

A few weeks ago, **Novartis** (NYSE: NVS) received unanimous FDA approval for its CAR-T therapy for the treatment of pediatric and young adult patients with B-cell acute lymphoblastic leukemia.

That now paves the way for approval in four months of Kite's KTE-C19 for patients with non-Hodgkin lymphoma.

How effective is this therapy?

At 8.7 months, 82% of patients saw their tumors shrink, with 39% in complete remission and responses ongoing in the other 44% of patients.

Because the process is complex and individualized, CAR-T drugs cannot be mass-produced. But Kite will have a huge first-mover advantage.

CAR-T therapies may also replace some stem cell transplants and will likely be priced along those lines. The price tag will come in somewhere between $300,000 and $700,000.

Because the drug is in the experimental stage, most patients didn't receive the treatment until they were told they had a 50% chance of living less than six months.

Yet the dramatic response rate has raised expectations about the therapy's potential.

Industry analysts estimate that in 10 years, immune-based treatments will generate up to $70 billion a year in sales. That will make them the most valuable class of drugs in history.

Sales were up 92% in the most recent quarter. But revenue should triple between this year and next. ■

THE OXFORD TRADING PORTFOLIO

An active and diversified portfolio of the market's most compelling opportunities.

COMPANY/SYMBOL	REC. DATE	REC. PRICE	CURR. PRICE	RATING	TRAILING STOP	TOTAL GAINS
American Water Works (NYSE: AWK)	Apr-16	$68.59	$81.36	Buy	$61.97	22.0%
Check Point Software Technologies Ltd. (Nasdaq: CHKP)	May-14	$66.96	$104.99	Buy	$86.79	56.8%
Chicago Bridge & Iron (NYSE: CBI)	**Jul-17**	**$18.17**	**$11.63***	**Sell**	**$14.06**	**-36.0%**
Diageo PLC (NYSE: DEO)	Mar-09	$49.80	$129.08	Buy	$99.72	207.5%
HealthEquity (Nasdaq: HQY)	Nov-16	$36.75	$46.14	Buy	$40.85	25.6%
iShares MSCI Emerging Markets Fund (NYSE: EEM)	Nov-15	$35.94	$42.82	Buy	$33.20	22.9%
Laboratory Corp. of America (NYSE: LH)	Oct-15	$118.29	$156.40	Buy	$120.88	32.2%
Match Group (Nasdaq: MTCH)	Dec-16	$17.49	$18.17	Buy	$15.03	3.9%
Owens & Minor Inc. (NYSE: OMI)	**Nov-09**	**$28.65**	**$28.97***	**Sell**	**$29.78**	**25.7%**
PayPal (Nasdaq: PYPL)	Jun-16	$39.06	$58.02	Buy	$45.11	48.5%
Philip Morris Int'l (NYSE: PM)	Mar-09	$35.63	$114.22	Buy	$91.39	300.4%
PVH Corp. (NYSE: PVH)	Feb-16	$66.41	$121.63	Buy	$93.23	83.4%
REV Group (NYSE: REVG)	Jun-17	$26.02	$25.21	Buy	$23.09	-2.9%
Rio Tinto PLC (NYSE: RIO)	Mar-16	$26.84	$45.37	Buy	$35.89	74.7%
Ryanair (Nasdaq: RYAAY) ***ADR***	Jun-15	$69.74	$115.17	Buy	$87.85	67.5%
Stryker Corp. (NYSE: SYK)	Aug-17	$145.37	$143.91	Buy	$110.90	-1.0%
TJX Companies (NYSE: TJX)	May-12	$41.09	$70.26	Buy	$61.20	81.3%
TransUnion (NYSE: TRU)	Jul-17	$43.32	$45.67	Buy	$34.63	5.4%
Under Armour (NYSE: UA)	Mar-17	$19.41	$16.82	Hold	$15.94	-13.3%
WisdomTree Japan Small Cap (NYSE: DFJ)	Feb-10	$39.90	$72.19	Buy	$55.01	98.4%

Note: If a "Buy" recommendation pulls back to within 5% of our protective stop, we routinely move it to a "Hold." If the stock resumes its upward climb, we will move it back onto our "Buy" list.

THE TEN-BAGGERS OF TOMORROW PORTFOLIO

A select group of more speculative stocks with the potential to rise tenfold or more.

COMPANY/SYMBOL	REC. DATE	REC. PRICE	CURR. PRICE	RATING	TOTAL GAINS
Accelerate Diagnostics (Nasdaq: AXDX)	Sept-16	$22.33	$21.10	Buy	-5.5%
Exelixis (Nasdaq: EXEL)	**Sept-17**	**New**	**New**	**Buy**	**New**
Glaukos (NYSE: GKOS)	Dec-16	$34.10	$36.31	Buy	6.5%
Intrexon Corp. (NYSE: XON)	Feb-17	$24.74	$18.66	Buy	-24.6%
Kite Pharma (Nasdaq: KITE)	Oct-16	$55.10	$120.60	Buy	118.9%
Momo Inc. (Nasdaq: MOMO)	Apr-17	$33.66	$42.57	Buy	26.5%
Proofpoint (Nasdaq: PFPT)	Oct-16	$74.56	$85.20	Buy	14.3%

Note: We do not use our 25% trailing stop in this portfolio. Instead, a sell recommendation will be triggered if a company misses the quarterly consensus earnings estimate by 25% or more – or if we believe the company's business prospects have changed for the worse in some fundamental way.

THE OXFORD ALL-STAR PORTFOLIO

A diversified basket of funds and holding companies managed by some of the world's top-performing money managers.

COMPANY/SYMBOL	REC. DATE	REC. PRICE	CURR. PRICE	RATING	TRAILING STOP	TOTAL GAINS
Berkshire Hathaway B Shares (NYSE: BRK-B)	Jan-01	$44.58	$176.36	Buy	None	295.6%
Equity Residential (NYSE: EQR)	Jul-01	$28.05	$67.08	Buy	None	279.6%
Icahn Enterprises L.P. (Nasdaq: IEP)^	Nov-13	$78.23	$54.17	Buy	None	-0.4%
Markel Corp. (NYSE: MKL)	Jul-15	$789.45	$1,050.89	Buy	None	33.1%
Templeton Dragon Fund (NYSE: TDF)	May-02	$9.20	$20.68	Buy	None	422.9%
Templeton Emerg. Mkts. Fund (NYSE: EMF)	Jan-02	$8.80	$15.57	Buy	None	269.2%

Note: The All-Star managers make buy and sell decisions within these securities themselves. We do not use trailing stops here.

THE GONE FISHIN' PORTFOLIO

A simple but sophisticated long-term investment system based on a Nobel Prize-winning strategy.

COMPANY/SYMBOL	REC. DATE	REC. PRICE	CURR. PRICE	RATING	ALLOCATION	TOTAL GAINS
Vanguard Small Cap Index (NAESX)	Apr-03	$15.12	$63.60	Buy	15%	365.8%
Vanguard Total Stock Mkt. Index (VTSMX)	Apr-03	$19.59	$60.74	Buy	15%	256.3%
Vanguard Emerg. Mkts. Index (VEIEX)	Apr-03	$7.26	$26.92	Buy	10%	362.8%
Vanguard Europ. Stock Index (VEURX)	Apr-03	$14.89	$30.10	Buy	10%	191.5%
Vanguard High-Yield Corp. Fund (VWEHX)	Apr-03	$6.02	$5.94	Buy	10%	93.2%
Vanguard Inflation-Protected Securities Fund (VIPSX)	Apr-03	$12.09	$13.23	Buy	10%	61.7%
Vanguard Pacific Stock Index (VPACX)	Apr-03	$5.56	$12.69	Buy	10%	190.5%
Vanguard Short-Term Investment (VFSTX)	Apr-03	$10.82	$10.71	Buy	10%	45.1%
Vanguard Prec. Metals and Mining (VGPMX)	Apr-03	$9.98	$10.50	Buy	5%	187.9%
Vanguard REIT Index (VGSIX)	Apr-03	$12.08	$27.45	Buy	5%	233.5%

Note: The Gone Fishin' strategy requires annual rebalancing and does not require the use of trailing stops. These prices do not reflect dividends.
^ Adjusted buy price based on averaging down on March 1, 2016, at $63.29.
Prices as of 8/10/17 I Note: For the absolute latest updates on all of *The Oxford Communiqué*'s portfolios, visit our website at www.oxfordclub.com.
*Current price based on official sell date

The Oxford Communiqué's portfolios fit into the **Core Portfolio**, **Blue Chip Outperformers** and **Targeted Trading** levels of the Oxford Wealth Pyramid. For more information, go here: www.oxfordclub.com/wealth-pyramid.

CEO & Executive Director — Julia Guth
Chief Investment Strategist — Alexander Green
Chief Income Strategist — Marc Lichtenfeld
Emerging Trends Strategist — Matthew Carr
Managing Editor — Samuel Taube
Managing Copy Editor — Anne Mathews
Event Director — Samuel Taube
Director of Research — Ryan Fitzwater
Art Director — Alison Kassimir
Graphic Designer — Chelsea Centineo

Basic dues for subscribers to *The Oxford Communiqué* are $249 a year. The issue is published monthly by The Oxford Club, LLC, 105 W. Monument Street, Baltimore, MD 21201. Non-U.S. dues are higher and vary from country to country.
Send address changes to *The Oxford Communiqué*, 105 W. Monument Street, Baltimore, MD 21201. For questions regarding the status of your membership, call Member Services at 443.353.4056. Our website is: www.oxfordclub.com.